Recent data from LLY on Retatrutide (as well as other promising solutions presented at the American Diabetes Association conference) have made me consider something that seems inevitable on the surface, but the timeline of which may be greatly accelerated: obesity may have a cure (specifically - diabesity, the word for diabetes and obesity as comorbidities) in these new medications
GLP-1 Medications GLP1 medications offer a science-based method for long-term weight management, designed to work with your bodys natural appetite signals rather than override them
Follow-up will occur over 12 months, with an additional phone call 30 days after treatment discontinuation
These combinations support glow, firmness, and barrier health
Tirzepatide (Mounjaro, Zepbound) : A dual GLP-1/GIP receptor agonist approved for diabetes and weight management
At Perfect B, we see consistent results with both protocols on roughly the same timeline